Literature DB >> 12468825

Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome.

J C Packham1, M A Hall.   

Abstract

OBJECTIVE: To examine the clinical and functional outcome of adults with juvenile idiopathic arthritis (JIA) using the recent World Health Organization/International League Against Rheumatism (ILAR) classification. PATIENTS AND METHODS: Two hundred and fifty-nine adults with long-standing JIA (average disease duration 28.3 yr) were eligible for the study; 246 (95%) attended for an interview, clinical examination and notes review and 231 (89.2%) returned a comprehensive functional and psychosocial self-assessment questionnaire.
RESULTS: Of all patients, 43.3% had active arthritis clinically and 54.4% on laboratory measures (C-reactive protein). Clinical inflammation was less common in systemic-onset JIA. The percentage of all patients with severe disability (Health Assessment Questionnaire score >1.5) was 42.9. Uveitis occurred frequently in the oligoarticular-onset and enthesitis-related subsets. Over 30% of the extended oligoarticular group with uveitis developed glaucoma compared with none of the enthesitis group.
CONCLUSIONS: Adults with JIA often have significant levels of disability, often related to continuing active disease over prolonged periods. There is a clear need for good transition from paediatric to high-quality adult rheumatology care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468825     DOI: 10.1093/rheumatology/41.12.1428

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  86 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Systemic Juvenile Idiopathic Arthritis with Amyloidosis: An Uncommon Complication with a Favourable Outcome.

Authors:  Avinash Sharma; Anju Gupta; Suvradeep Mitra; Ritambhra Nada; Sagar Bhattad; Surjit Singh
Journal:  Indian J Pediatr       Date:  2015-10-07       Impact factor: 1.967

3.  [Transition clinic--it is not always a simple segue in rheumatology for adults].

Authors:  K Minden; M Niewerth; A Zink; G Ganser
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

4.  A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis.

Authors:  Lauren A Henderson
Journal:  Arthritis Rheumatol       Date:  2019-05-27       Impact factor: 10.995

Review 5.  Transition of care from paediatric to adult rheumatology.

Authors:  Janet E McDonagh
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

6.  Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects.

Authors:  Megan L Krause; Jorge A Zamora-Legoff; Cynthia S Crowson; Theresa Wampler Muskardin; Thomas Mason; Eric L Matteson
Journal:  Semin Arthritis Rheum       Date:  2016-07-18       Impact factor: 5.532

7.  [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].

Authors:  K Minden; J Klotsche; M Niewerth; G Horneff; A Zink
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

Review 8.  Assessment and management of pain in juvenile idiopathic arthritis.

Authors:  Jennifer N Stinson; Nadia J C Luca; Lindsay A Jibb
Journal:  Pain Res Manag       Date:  2012 Nov-Dec       Impact factor: 3.037

9.  Caregiver demand and parent distress in juvenile rheumatic disease: the mediating effect of parent attitude toward illness.

Authors:  Jamie L Ryan; Larry L Mullins; Rachelle R Ramsey; Margaret S Bonner; James N Jarvis; Stephen R Gillaspy; John M Chaney
Journal:  J Clin Psychol Med Settings       Date:  2013-09

Review 10.  Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.

Authors:  Kristen Hayward; Carol A Wallace
Journal:  Arthritis Res Ther       Date:  2009-02-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.